CN1405176A - Steride, its systhesis method and use - Google Patents

Steride, its systhesis method and use Download PDF

Info

Publication number
CN1405176A
CN1405176A CN 02145066 CN02145066A CN1405176A CN 1405176 A CN1405176 A CN 1405176A CN 02145066 CN02145066 CN 02145066 CN 02145066 A CN02145066 A CN 02145066A CN 1405176 A CN1405176 A CN 1405176A
Authority
CN
China
Prior art keywords
compound
reaction
perhaps
become
oac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 02145066
Other languages
Chinese (zh)
Other versions
CN1221564C (en
Inventor
田伟生
许启海
彭小文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Priority to CN 02145066 priority Critical patent/CN1221564C/en
Publication of CN1405176A publication Critical patent/CN1405176A/en
Application granted granted Critical
Publication of CN1221564C publication Critical patent/CN1221564C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Steroid Compounds (AREA)

Abstract

A kind of compound, synthesizing method and its use is disclosed in the invention, whose structure formula is 1:R1=OH, OAc, OMs, OTs, OTBS, OTBDPS etc. or R1, R2 forming 3,5-three-membered ring structure; R2=x, or R1, R2 forming 1,5-three-membered ring structure, or R2, R3 forming 5,6-double bonds; R3=OH, OAc, OMs, OTs, OTBS, OTBDPS X etc. or R2, R3 forming 5,6-double bonds; R4=H, OH, SPh, S(CH2)nSA etc. or R4, R5 forming carbonic bonds, or R4, R5=S(CH2)nS, (n=2,3, etc.), or R5, R6 forming 16, 17 double bonds, or R5, R7 forming 16, 22 aether bond; R6=H, or R5, R6 forming 16, 17 double bonds; R5, R7 forming 16, 22 aether bond, or R7, R8 forming carbonic bonds; R5=H or R7, R8 forming carbonic bonds. Thereinto, Ac is acetyl, Ms is methylsulfonyl, Ts is toluenesulfonyl, TBS is butyl dimethylsilyl, TBDSPS is butyl dipheny Si-based, X is halogen, SPh is phenylthio.

Description

Steroidal compounds, preparation method and use
Technical field
The present invention relates to the steroidal compounds of a class formation novelty, relate to the synthetic method of this compounds, with and in the purposes of synthesis of natural product OSW-1 sapogenin.
Technical background
1992, the Y.Sashida research group of Tokyo University medicine institute isolates a series of saponins with cholesterol skeleton from the underground bulb of a kind of evergreen ornamental plant Ornithogalum saunderside that originates in South Africa, they just the 3-position of glucoside unit and disaccharides aglucon 2 "-slightly different on the position; all have extremely strong anti-tumor activity; the OSW-1 as main extract has extremely strong lethality to multiple malignant cell, than present clinical employed several cancer therapy drugs such as mitomycin (Mitomycin); Zorubicin (Adriamycin); the effectiveness of taxol (Taxol) etc. exceeds 10-100 times.What is more important, though OSW-1 has good active to multiple malignant cell, it is to the but very little (IC of the murder by poisoning of people's normal lung cell 501500nM) (referring to Phytochemistry, 1992,31,3969; Bioorg.﹠amp; Med.Chem.Lett., 1997,7,633), its concrete structure is as follows:
Figure A0214506600061
R 1 R 2
1 H p-Methoxybenzoyl(OSW-1)
2 H 3，4-Dimethoxybenzoyl
3 H (E)-cinnamoyl
4 Glc p-Methoxybenzoyl
5 Glc (E)-cinnamoyl
Since extremely strong antitumour activity that OSW-1 had with and the unique chemical structure, and it is less to contain the plant resources of this compound, so the chemosynthesis of this compounds has caused extensive concern.At present, existing three groups have finished the synthetic of OSW-1 and glucoside unit thereof.The synthetic route of Hui Yongzheng group as shown below (referring to J.Org.Chem., 1999,64; 202); they are starting raw material with dehydroepiandros-sterone 6, generate by the Wittig reaction to prolong 7 of two carbon, introduce 16 by the ene reaction then; the two keys of 17-also prolong side chain; obtain after the compound 9, protect the 22-carbonyl earlier, dihydroxylation obtains cis-glycol 11 again; make 16-hydroxyl configuration reversal by oxidation-reduction then, the OSW-1 saponin 13 that is protected.
Figure A0214506600071
The synthesis strategy of P.L.Fuchs group and above similar (referring to Tetra.Lett., 1998,39,1099).Z.D.Jin group introduces hydroxyl and is oxidized to carbonyl in 7 16-position earlier after also obtaining 7 by Wittig reaction, then by the addition reaction of copper lithium reagent introduce side chain (referring to J.Arm.Chem.Soc., 2001,123,3367; J.Arm.Chem.Soc., 2002,124,6576).
As seen, currently used synthetic route is a starting raw material with dehydroepiandros-sterone 6 all, and 6 of dehydroepiandros-sterones are degraded through six-step process by natural diosgenin (Diosgenin), total recovery between 25-50% (referring to J.Arm.Chem.Soc., 1940,62,3350; J.Org.Chem., 1956,21,520).
a，Ac 2O，200℃；b，CrO 3，HOAc；c，NaOAC；d，NH 2OH?HCl；e，
p-Acetamidobenzenesulfonyl?chloride；f，K 2CO 3，MeOH。
Obviously, this synthesis strategy of steroid sapogenines that utilizes has a lot of shortcomings,, complex operation step outmoded such as degradation technique, environmental pollution are serious or the like, the more important thing is that the carbon skeleton of steroid sapogenines and functional group thereof fail to be fully used, and this must cause the significant wastage of resource.
Summary of the invention
The purpose of this invention is to provide a class steroidal compounds.
Another object of the present invention provides the method for synthetic above-mentioned steroidal compounds.
Purpose of the present invention also provides a kind of purposes of above-mentioned steroidal compounds, and these compounds are important intermediate of synthetic OSW-1 and sapogenin thereof.
The structure of steroidal compounds of the present invention is as follows:
Figure A0214506600081
R 1=OH, OAc, OMs, OTs, OTBS, OTBDPS etc., perhaps R 1, R 2Become 3,5-triatomic ring, i.e. R 1, R 2Be singly-bound; R 2=X, perhaps R 1, R 2Become 3,5-triatomic ring, i.e. R 1, R 2Be singly-bound, perhaps R 2, R 3Become 5, the two keys of 6-; R 3=OH, OAc, OMs, OTs, OTBS, OTBDPS, X etc., perhaps R 2, R 3Become 5, the two keys of 6-; R 4=H, OH, SPh, S (CH 2) nSAc etc., perhaps R 4, R 5Become carbonyl, perhaps R 4, R 5=S (CH 2) nS, (n=2,3, etc.); R 5=SPh, perhaps R 4, R 5Become carbonyl, perhaps R 4, R 5=S (CH 2) nS, (n=2,3, etc.), perhaps R 5, R 6Become 16,17-two key, perhaps R 5, R 7Become 16, the 22-ehter bond; R 6=H, perhaps R 5, R 6Become 16, the two keys of 17-; R 7=R 5, R 7Become 16,22-ehter bond, perhaps R 7, R 8Become carbonyl; R 8=H, perhaps R 7, R 8Become carbonyl.Wherein, Ac is an ethanoyl, and Ms is a methylsulfonyl, and Ts is a p-toluenesulfonyl, and TBS is that tertiary butyl dimethyl is silica-based, and TBDPS is that tert-butyl diphenyl is silica-based, and X is a halogen, and SPh is a thiophenyl.
In order to understand steroidal compounds of the present invention better, be example with the steroidal compounds of following structural formula:
Figure A0214506600092
R 3=OH, OAc, OMs, OTs, OTBS, OTBDPS etc.; R 4=H, OH.
Figure A0214506600093
R 3=OH, OAc, OMs, OTs, OTBS, OTBDPS etc.
Figure A0214506600094
R 1=OH, OAc, OMs, OTs, OTBS, OTBDPS etc.; R 4, R 5=carbonyl, SPh, S (CH 2) nS (n=2,3, etc.). R 1=OH, OAc, OMs, OTs, OTBS, OTBDPS etc.; R 4=SPh, S (CH 2) nSAc (n=2,3, etc.).The synthetic route of steroidal compounds of the present invention is as follows:
Figure A0214506600101
(1), in non-protonic solvent and under 0-50 ℃ of condition, in the mixture of substrate and mercaptan, drips Lewis acid (1: 2-5: 1-2), reacted 5-30 hour, obtain compound 14.Solvent can be methylene dichloride (CH 2Cl 2), trichloromethane (CHCl 3) etc.; Lewis acid can be aluminum chloride (AlCl 3), boron trifluoride diethyl etherate (BF 3Et 2O), titanium tetrachloride (TiCl 4) etc.
(2), in polar solvent, compound 14 and Raney Ni (Raney Ni) backflow 1-3 days, every mmole compound 14 usefulness 1-2 restrain Raney Ni, get compound 15.Raney Ni can be W-2 type or W-6 type etc.
(3), in non-protonic solvent and under 0-50 ℃, under organic base catalytic, compound 15 generates sulphonate with the SULPHURYL CHLORIDE reaction, and compound 15, SULPHURYL CHLORIDE and organic bases mol ratio are 1: 1-2: 0.5-2; In polar solvent, sulphonate and inorganic weak bases backflow 1-3 days, the mol ratio of sulphonate and inorganic weak bases is 1: 0.5-3; Products therefrom is dissolved in aceticanhydride, and reaction generated compound 16 in 5-15 hour under organic base catalytic; Wherein the mol ratio of organism, aceticanhydride and organic bases is 1: 2-10: 0.5-2; Wherein SULPHURYL CHLORIDE is methylsulfonyl chloride or Tosyl chloride (TsCl); Inorganic weak bases can be K 2CO 3, Na 2CO 3, KHCO 3, NaHCO 3, KOAc, NaOAc etc.
(4), in the buffered soln of the polar solvent and the disodium EDTA aqueous solution, compound 16, potassium hydrogen persulfate (oxone) and NaHCO 3,-10-50 ℃ of reaction 2-25 hour, compound 17 and 18; Same method makes compound 17 be converted into compound 18; Compound 16 or 17, potassium hydrogen persulfate and NaHCO 3Mol ratio be 1: 2-8: 8-30; The pH value of buffered soln is 7-9;
(5), in one or more polar solvent and under tosic acid (PTSA) catalysis, generated compound 19 in compound 18 backflow 10-60 minutes, compound 18 is 1 with the mol ratio of tosic acid: 0.1-0.5;
(6), aceticanhydride and compound 19 generated compound 20 in 10-60 minute in 100-140 ℃ of reaction under organic base catalytic, and the mol ratio of compound 19, aceticanhydride and organic bases is 1: 2-10: 0.5-2;
(7), in the organic solvent, compound 20, mercaptan and Lewis acid obtain compound 21 0-50 ℃ of reaction 1-4 hour; Compound 20 is 1 with mercaptan and lewis acidic mol ratio: 1-3: 1-2;
(8), in organic solvent, compound 21, catalyzer and aceticanhydride 0-50 ℃ of reaction 5-180 minute, obtain compound 22; The mol ratio of compound 21, aceticanhydride and catalyzer is 1: 2-10: 0.01-2;
(9), in organic solvent, compound 19 or 20, mercaptan and Lewis acid 0-50 ℃ of reaction 1-4 hour, add aceticanhydride, react 5-180 minute, obtain compound 21; Compound 19 or 20, mercaptan, aceticanhydride and lewis acidic mol ratio are 1: 1-3: 10-50: 1-2;
(10), in polar solvent, compound 22 with 25-100 ℃ of reaction 0.5-5 hour, every mmole compound 22 usefulness Raney Ni 1-2 gram must compound 9;
Lewis acid is AlCl described in the above-mentioned reaction 3, BF 3Et 2O or TiCl 4Described catalyzer is AlCl 3, BF 3Et 2O, TiCl 4Or HClO 4Described organic bases is triethylamine, pyridine or 4-N, the N-dimethyl aminopyridine; Described non-protonic solvent is CH 2Cl 2, CHCl 3, CCl 4Or ether; Described polar solvent is water, acetone, ethanol, trichloromethane, methylene dichloride, 1,4-diox (dioxane), toluene or acetonitrile; Mercaptan can be thiophenol (PhSH), dithioglycol, dimercaptopropane etc.
Steroidal compounds of the present invention can be used for the synthetic of OSW-1 sapogenin, is raw material with compound 22, and the method for reference literature (referring to Tetra.Lett., 1998,39,1099; J.Org.Chem., 1999,64,202), its reaction formula is as follows, the OSW-1 sapogenin compound 13 that can be protected:
Wherein (11), compound 22 is dissolved in the polar solvent, adds Raney Ni (every mmole substrate restrains with 1-2), and 25-100 ℃ was reacted 0.5-5 hour, got compound 9.Solvent can be an acetone, various alcohols; Raney Ni can be W-2 type or W-6 type etc.
The operation of reaction (12)-(17) reference literature carry out (referring to Tetra.Lett., 1998,39,1099; J.Org.Chem., 1999,64,202).
Major advantage of the present invention has:
1. be basic raw material directly, obtained the OSW-1 sapogenin compound 13 of 3-position and the protection of 22-position by the reaction of 17 steps with 9.3% total recovery with natural diosgenin.This synthesis strategy has made full use of natural steroid saponin Diosgenin: utilize its carbon skeleton to synthesize side chain, utilize its functional group further to transform.This is than the more economical rationality of strategy that earlier it is degraded into epiandrosterone and then introduces carbochain.
2. utilize the oxone oxidation to open the E ring, avoid using with serious pollution chromic acid oxidation.
3. diketone compound (compound 19 or 20) is at BF 3Et 2Following and the thiol reactant of O catalysis obtains 16-thio ketal ization product 21 regiospecificity, and the 22-carbonyl does not react.
4. obtain the enol thioether by the thio ketal ization open loop and make up 16, the two keys of 17-are committed steps of the present invention, and the method for fractional steps and the one kettle way of the present invention's development all can be realized this conversion.
Specific implementation method
To help to understand the present invention by following specific implementation method, but not limit content of the present invention.
Embodiment 13 beta-hydroxies-26,26-hexichol sulfenyl furostan-5 (6)-alkene (14a) synthetic
Diosgenin 10.000g (24.2mmol) is dissolved in 100ml CH 2Cl 2In, (121.13mmol 5.0eq), slowly drips BF again to add PhSH12.38ml 3Et 2O 6.11ml (48.6mmol, 2.0eq), stirring at room to raw material disappears, and adds the ethyl acetate dilution, and organic phase is washed till neutrality, MgSO with saturated NaCl solution again with 2N NaOH solution washing 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets white solid 13.138g (88.3%).C 39H 52O 2S 2，FW616；[α] D 17＝-45.1°(C＝0.89，CHCl 3)；mp?53-54℃； 1H-NMR：7.49-7.24(10H，m，Ar)，5.37(1H，d，J＝4.2Hz，6-H)，4.50(1H，d，J＝3.0Hz， 26-H)，4.27(1H，m，16-H)，3.52(1H，m，3-H)，3.24(1H，m，22-H)，1.17(3H，d， J＝6.6Hz，21-Me)，1.05(3H，s，19-Me)，0.95(3H，d，J＝6.6Hz，27-Me)，0.80(3H，s， 18-Me)；MS(EI)：507(M +-109，66.9％)，271(100％)；IR：3352，1583.
Synthesizing of embodiment 23 beta-hydroxy furostans-5 (6)-alkene (15)
11.000g 14a is dissolved among the anhydrous EtOH of 440ml, adds the about 30g of W-2 type Raney Ni, be back to raw material and disappear, filter, residue is with anhydrous EtOH thorough washing, and filtrate is spin-dried for, must white solid 6.653g (93.1%).C 27H 44O 2，FW?400；[α] D 17＝-61.7°(C＝1.01，CHCl 3)；mp?69-70℃； 1H-NMR：5.34(1H，d，J＝5.4Hz，6-H)，4.30(1H，m，16-H)，3.52(1H，m，3-H)，3.31(1H， m，22-H)，1.02(3H，s，19-Me)，0.99(3H，d，J＝7.2Hz，21-Me)，0.89(6H，d，J＝6.6Hz， 26，27-Me)，0.81(3H，s，18-Me)；MS(EI)：400(M +)，271(100％)；IR：3381，1052.
Embodiment 36 β-acetoxy-3 α, 5 α-ring furostan (16) synthetic
1.111g 15 is dissolved in the 5ml dry pyridine, and ice bath adds down 2.448g TsCl, and room temperature reaction to raw material disappears, and adds the ethyl acetate dilution, and organic phase is with saturated NaCl solution washing four times, MgSO 4Drying is filtered the pressure reducing and steaming solvent.The gained crude product is dissolved in the 200ml acetone, adds the 10ml aqueous solution of 3.5g KOAc, and be back to raw material and disappear, the pressure reducing and steaming organic solvent, the ethyl acetate extraction organism, organic phase is with saturated NaCl solution washing, MgSO 4Drying is filtered the pressure reducing and steaming solvent.The gained crude product is dissolved in 10ml Ac 2In O and the 1ml pyridine, add a small amount of DMAP, room temperature reaction 4h reacts completely.Add saturated NaHCO 3Solution is not emerged to there being bubble, ethyl acetate extraction, and organic phase is used NaHCO respectively 3Solution and saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets thickness oily matter 0.923g (three step productive rates are 75.2%).C 29H 46O 3；FW?442；[α] D 17＝+38.4°(C＝0.97，CHCl 3)； 1H-NMR：4.51(1H，t，J＝2.8Hz，6-H)，4.28(1H，m，16-H)，3.30(1H，m，22-H)，2.05(3H， s，OAc)，1.03(3H，s，19-Me)，1.00(3H，d，J＝6.6Hz，21-Me)，0.90?and?0.87(each?3H， d，J＝6.6Hz，26，27-Me)，0.86(3H，s，18-Me)，0.48-0.40(2H，m，4-H)；MS(EI)：382(M +-60，100％)，367(18％)，253(90％)；IR：1734.
Embodiment 4 16 Alpha-hydroxies-6 β-acetoxy-3 α, 5 α-ring furostan (17) and 6 β-acetoxyl group
-3 α, 5 α-ring cholestane 16,22-diketone (18) synthetic
16 440mg are dissolved in 2ml CH 2Cl 2In, add 16ml acetone and 8.5ml EDTA Na 2The aqueous solution, ice bath add 2.449g (4eq) oxone and 1.255g (15eq) NaHCO down 3, reaction 6h, raw material disappears.The pressure reducing and steaming organic solvent, CH 2Cl 2Extraction, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets 143mg 18 (31.5%) and 277mg 17 (60.8%).
17 1040mg are dissolved in 5ml CH 2Cl 2In, add 38ml acetone and 21ml EDTA Na 2The aqueous solution, ice bath add 5.925g (4eq) oxone and 3.037g (15eq) NaHCO down 3, rise to room temperature naturally and spend the night, the samely carry out aftertreatment, get 347mg 18 (33.5%, 98.5% compound 17) and 686mg 17 (66.0%) with respect to reaction.Compound 17:C 29H 46O 4FW458; [α] D 17=+10.3 ° of (C=0.82, CHCl 3); Mp 64-66 ℃; 1H-NMR:4.51 (1H, t, J=2.8Hz, 6-H), 3.85 (1H, m, 22-H), 2.03 (3H, s, OAc), 1.04 (3H, d, J=6.7Hz, 21-Me), 1.01 (3H, s, 19-Me), 0.88 (6H, d, J=6.6Hz, 26,27-Me), 0.83 (3H, s, 18-Me), and 0.51-0.41 (2H, m, 4-H); MS (EI): 425 (M +-18-15,22%), 366 (100%); IR:3414,1735. compound 18:C 29H 44O 4FW456; [α] D 17=-102 ° of (C=1.00, CHCl 3); Mp 108-110 ℃; 1H-NMR:4.55 (1H, t, J=2.8Hz, 6-H), 2.06 (3H, s, OAc), 1.06 (3H, d, J=7.8Hz, 21-Me), 1.04 (3H, s, 19-Me), 0.91 (6H, d, J=6.3Hz, 26,27-Me), 0.85 (3H, s, 18-Me), 0.52-0.45 (2H, m, 4-H); MS (EI): 397 (M +-59,7.3%) 381 (M, +-15-60,17.4%), 297 (100%); IR:1732.
Embodiment 53 beta-hydroxy cholestane-5 (6)-alkene-16,22-diketone (19) synthetic
In the container that fills 1.853g 18, add 100ml dioxane and 130ml H 2O adds 157mgPTSA again, and backflow 0.5h steams dioxane, filters, and solid washes with water, and dry back rapid column chromatography separates, and gets white solid 1.627g (97%).C 27H 42O 3；FW?414；[α] D 17＝-201.3°(C＝0.80，CHCl 3)；mp?147-148℃； 1H-NMR：5.35(1H，d，J＝5.1Hz，6-H)，3.54(1H，m，3-H)，1.06(3H，d，J＝7.2Hz，21-Me)， 1.04(3H，s，19-Me)，0.91(6H，d，J＝6.0Hz，26，27-Me)，0.81(3H，s，18-Me)；MS(EI)：400(M ++1-15，2％)，344(10.8％)，316(13.3％)；IR：3421，1739，1709；EA：Calcd(％)：C78.21 H10.21
Found(％)：C78.13 H9.92.
Embodiment 63 β-acetoxyl group cholestane-5 (6)-alkene-16,22-diketone (20) synthetic
Compound 19 178mg are dissolved in 2.5ml Ac 2O and 0.1ml pyridine, backflow 10min, raw material disappears.Add saturated NaHCO 3Solution adds solid NaHCO then 3Do not emerge to there being bubble, ethyl acetate extraction, organic phase is used saturated NaHCO respectively 3Solution and saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets white solid 193mg (98.4%).C 29H 44O 4；FW?456； 1H-NMR：5.37(1H，d，J＝5.1Hz，6-H)，4.62(1H，m，3-H)，2.04(3H，s，OAc)，1.06(3H，d， J＝6.0Hz，21-Me)，1.05(3H，s，19-Me)，0.91(6H，d，J＝6.0Hz，26，27-Me)，0.81(3H， s，18-Me)；MS(EI)：441(M +-15，5.4％)，397(11.5％)，340(100％)；IR：1732，1712.
Synthesizing of embodiment 73 beta-hydroxies-16-dimercaptopropane ketal cholestane-5 (6)-alkene-22-ketone (21c)
Compound 19 245mg are dissolved in 8ml CH 2Cl 2, add the 60ul dimercaptopropane, drip 75ul BF then 3Et 2O, room temperature reaction 2.5h, raw material disappears.Ethyl acetate extraction, organic phase are used saturated NaHCO respectively 3Solution and saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets white powder compound 261mg (88%).C 30H 48O 2S 2FW 504; [α] D 21=-33.4 ° of (C=1.0, CHCl 3); Mp 113-115 ℃; 1H-NMR:5.35 (1H, d, J=5.1Hz, 6-H), 3.54 (1H, m, 3-H), 3.27-2.90 (4H, m, SCH 2CH 2CH 2S), 1.09 (3H, d, J=6.8Hz, 21-Me), 1.00 (3H, s, 19-Me), 0.97 (3H, s, 18-Me), 0.91 (6H, d, J=5.7Hz, 26,27-Me); MS (EI): 504 (M +, 11.2%), 404 (M +-100,68%); IR:3421,1714. embodiment, 83 β-acetoxyl group-16-(ethanoyl-1,3-third disulfide group)-cholestane-5 (6), 16 (17)-diene-22-
Synthetic (by 21 Synthetic 2s 2) of ketone (22c)
Compound 21c 260mg is dissolved in 3ml CHCl 3With 4ml CCl 4In, add the 3ml aceticanhydride, drip 0.5ul 70%HClO then 4, room temperature reaction 2.5h, raw material disappears.Add the saturated NaHCO of 40ml 3Solution, ethyl acetate extraction, organic phase is used saturated NaHCO respectively 3Solution and saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets oily compound 197mg (65%).C 34H 52O 4S 2, FW 588; [α] D 21=+48.8 ° of (C=6.5, CHCl 3); 1H-NMR:5.40 (1H, d, J=4.6Hz, 6-H), 4.60 (1H, m, 3-H), 3.67 (1H, q, J=7.0Hz, 20-H), 2.95-2.71 (4H, m, SCH 2CH 2CH 2SAc), 2.34 (3H, s, SAc), 2.04 (3H, s, OAc), 1.21 (3H, d, J=7.0Hz, 21-Me), 1.04 (3H, s, 19-Me), 0.94 (3H, s, 18-Me), 0.88 (6H, d, J=5.7Hz, 26,27-Me); MS (EI): 588 (M +, 11%), 489 (M +-99,100%); IR:1734,1712,1695. embodiment, 93 β-acetoxyl group-16-(ethanoyl-1,3-ethylene dithiol base)-cholestane-5 (6), 16 (17)-diene-22-
Synthetic (by 19 or 20 Synthetic 2s 2) of ketone (22b)
Compound 20 2.290g are dissolved in 35ml HOAc, add 1.06ml HSCH 2CH 2SH drips 1.3ml BF then 3Et 2O, room temperature reaction 2.5h, raw material disappears.Add 20ml Ac again 2O, mixture becomes transparent salmon by white opacity immediately, reaction 20min, reaction finishes.Add saturated NaHCO 3Solution adds solid NaHCO then 3Do not emerge to there being bubble, ethyl acetate extraction, organic phase is used saturated NaHCO respectively 3Solution and saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets light yellow thickness oily matter 1.830g (63.5%).C 33H 50O 4S 2，FW?574； 1H-NMR：5.40(1H，d，J＝3.9Hz，6-H)，4.61(1H，m，3-H)，3.68(1H，q，J＝6.8Hz，20-H)， 2.98?and?2.81(4H，m，SCH 2CH 2S)，2.35(3H，s，SAc)，2.04(3H，s，OAc)，1.22(3H， d，J＝7.2Hz，21-Me)，1.05(3H，s，19-Me)，0.98(3H，s，18-Me)，0.87(6H，d，J＝5.7Hz， 26，27-Me)； 13C-NMR：210.975，195.100，170.507，153.387，139.916，131.031，122.109，73.787，
56.491，50.095，48.874，46.836，38.577，38.043，36.745，36.711，35.074，34.395，
32.975，31.250，30.594，30.067，29.746，27.625，22.434，22.350，21.389，20.419，
19.152，17.145，14.344；MS(EI)：574(M +，1.2％)，475(M +-99，100％)；IR：1734，1713，1696.
Synthesizing of embodiment 10 3 β-acetoxyl group cholestane-5 (6), 16 (17)-diene-22-ketone (9)
930mg 22b is dissolved among the anhydrous EtOH of 30ml, adds the about 3g of W-2 type Raney Ni, room temperature reaction 0.5h, raw material disappears, and filters, and residue is with anhydrous EtOH thorough washing, and filtrate is spin-dried for, and the rapid column chromatography separation gets white solid 641mg (90%).C 29H 44O 3FW 440; [α] D 17=+28.9 ° of (C=3.70, CHCl 3); Mp 69-70 ℃; 1H-NMR:5.37 (2H, m, 6-H and 16-H), 4.61 (1H, m, 3-H), 3.20 (1H, q, J=6.8Hz, 20-H), 2.04 (3H, s, OAc), 1.16 (3H, d, J=6.6Hz, 21-Me), 1.06 (3H, s, 19-Me), 0.87 (6H, d, J=6.1Hz, 26,27-Me), 0.85 (3H, s, 18-Me); MS (ESI): 441 (M ++ 1,100%); IR:1735,1714,1244. embodiment, 11 3 β-acetoxyl group cholestane-5 (6), 16 (17)-diene-22-ethylene ketal (10) synthetic
610mg 9 is dissolved in 8ml HC (OEt) 3And 5ml (CH 2OH) 2In, add 90mg PTSA, room temperature reaction 6.5h, raw material disappears.Add saturated NaCl solution, CH 2Cl 2Extraction, organic phase is with saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets solid 568mg (85%) in vain.C 31H 48O 4FW 484; 1H-NMR:5.67 (1H, d, J=1.8Hz, 16-H), 5.39 (1H, d, J=4.5Hz, 6-H), 4.61 (1H, m, 3-H), 3.96 (4H, brs, OCH 2CH 2O), 2.45 (1H, q, J=6.9Hz, 20-H), 2.04 (3H, s, OAc), 1.06 (3H, s, 19-Me), 1.03 (3H, d, J=7.2Hz, 21-Me), 0.85 and 0.87 (each 3H, d, J=6.7Hz, 26,27-Me), 0.82 (3H, s, 18-Me). embodiment 12 16 α, 17 alpha-dihydroxy-s-3 β-acetoxyl group cholestane-5 (6)-alkene-22-ethylene ketal (11)
Synthetic
522mg 10 is dissolved in 60ml ether and the 1ml pyridine, and-78 ℃ add 1.2eq OsO 4, rise to room temperature naturally, add CH 2Cl 2Make the solid dissolving, logical H 2S decomposing gas osmate filters residue CH 2Cl 2Thorough washing, filtrate is spin-dried for, and rapid column chromatography separates, and gets white solid 319mg (57.1%).C 31H 50O 6FW 518; 1H-NMR:5.37 (1H, d, J=4.8Hz, 6-H), 4.61 (1H, m, 3-H), 4.28 (1H, m, 16-H), 4.04 (1H, d, J=3.9Hz, 16-OH), 3.96 (4H, m, OCH 2CH 2O), 3.10 (1H, s, 17-OH), 2.03 (3H, s, OAc), 1.12 (3H, d, J=6.9Hz, 21-Me), 1.01 (3H, s, 19-Me), 0.87 and 0.85 (each 3H, d, J=6.5Hz, 26,27-Me), 0.78 (3H, s, 18-Me); MS (EI): 438 (M +-18-18-44,1.6%), 382 (M +-15-18-44-59,1.5%). embodiment 13 17 Alpha-hydroxies-3 β-acetoxyl group cholestane-5 (6)-alkene-22-ethylene ketal-16-ketone (12)
Synthetic
Under-78 ℃, the 3ml CH of 0.16ml dimethyl sulfoxide (DMSO) (DMSO) 2Cl 2Solution splashes into 0.2ml (COCl) 24ml CH 2Cl 2In the solution, behind the 20min, drip the 8ml CH of 290mg 11 2Cl 2Solution, reaction 20min drips 0.72ml Et again 3N, reaction removes low temperature behind the 40min, rises to room temperature naturally and continues reaction 20min, and ethyl acetate is diluted, and organic phase is with saturated NaCl solution washing three times, MgSO 4Drying is filtered, the pressure reducing and steaming solvent, and rapid column chromatography separates, and gets white solid 232mg (80.3%, 87%based onreacted 11).C 31H 48O 6；FW?516； 1H-NMR：5.31(1H，d，J＝5.1Hz，6-H)，4.71(1H，s，17-OH)，4.54(1H，m，3-H)，3.96(4H， m，OCH 2CH 2O)，2.68(1H，q，J＝7.8Hz，20-H)，1.97(3H，s，OAc)，0.98(3H，s， 19-Me)，0.95(3H，d，J＝7.5Hz，21-Me)，0.87(3H，s，18-Me)，0.83and0.81(each?3H， d，J＝6.9Hz，26，27-Me)；MS(EI)：499(M +-17，1.9％)，456(M +-60，7.2％)；IR：3408，1756，1734，1242.
Embodiment 14 3 β, 17 alpha-dihydroxy-cholestane-5 (6)-alkene-22-ethylene ketal-16-ketone (23) synthetic
171mg 12 is dissolved among the 150ml MeOH, adds 240mg K 2CO 3, ambient temperature overnight.The pressure reducing and steaming organic solvent is directly mixed the sample upper prop, gets white solid 158mg (100%).C 29H 46O 5FW 474; 1H-NMR:5.34 (1H, d, J=5.4Hz, 6-H), 4.77 (1H, s, 17-OH), 3.98 (4H, m, OCH 2CH 2O), 3.54 (1H, m, 3-H), 2.74 (1H, q, J=7.8Hz, 20-H), 1.04 (3H, s, 19-Me), 1.01 (3H, d, J=7.2Hz, 21-Me), 0.93 (3H, s, 18-Me), 0.89 and 0.87 (each 3H, d, J=6.4Hz, 26,27-Me); MS (EI): 474 (M +, 1.3%), 459 (M +-15,1.7%) 403 (M, +-71,7.1%) 331 (M, +143,14.3%); IR:3347,1748,1052. embodiment 15 17 Alpha-hydroxies-3 β-(dimethyl-tertiary butyl)-siloxy cholestane-5 (6)-alkene-22-ethylene glycol contracts
Synthesizing of ketone-16-ketone (24)
13mg 23 is dissolved among the dry DMF of 0.5ml, adds 2.5eq imidazoles (imidazole) and 2.0eq TERT-BUTYL DIMETHYL CHLORO SILANE (TBSCl), room temperature reaction 3h.Add entry and ethyl acetate, organic phase is with saturated NaCl solution washing three times, MgSO 4Drying is filtered, the pressure reducing and steaming organic solvent, and rapid column chromatography separates, and gets white solid 14mg (87%).C 35H 60O 5Si; FW 588; 1H-NMR:5.31 (1H, d, J=4.8Hz, 6-H), 4.75 (1H, s, 17-OH), 4.01 (4H, m, OCH 2CH 2O), 3.49 (1H, m, 3-H), 2.75 (1H, q, J=7.5Hz, 20-H), 1.03 (3H, s, 19-Me), 1.01 (3H, d, J=7.8Hz, 21-Me), 0.93 (3H, s, 18-Me), (0.90 15H, brs, 26,27-Me and t-Bu), 0.05 (6H, s, Me-Si). embodiment 16 16 β, 17 alpha-dihydroxy-s-3 β-(dimethyl-tertiary butyl)-siloxy cholestane-5 (6)-alkene-22-second
Synthesizing of glycol ketal (13)
69mg 24 is dissolved among the 5ml THF, and-15 ℃ add 57mg (1.3eq) CeCl down 37H 2O and 27mg (6.0eq) NaBH 4, rise to room temperature naturally, add water and stir, ethyl acetate extraction, organic phase is with saturated NaCl solution washing, MgSO 4Drying is filtered, the pressure reducing and steaming organic solvent, and rapid column chromatography separates, and gets white solid 66mg (94%), C 35H 62O 5Si; FW 590; 1H-NMR:5.29 (1H, d, J=4.8Hz, 6-H), 4.04 (6H, m, OCH 2CH 2O, 16-OH, 17-OH), 3.49 (1H, m, 3-H), 2.59 (1H, q, J=7.2Hz, 20-H), 1.18 (3H, d, J=7.2Hz, 21-Me), 0.99 (3H, s, 19-Me), (0.89 18H, brs, 18,26,27-Me and t-Bu), 0.05 (6H, s, Me-Si); 13C-NMR:141.374,121.094,116.453,86.754,81.519,72.527,64.040,62.803,
49.591，47.836，47.775，42.714，37.234，36.471，35.837，33.860，33.090，32.731，
32.700，32.013，31.868，31.845，28.250，25.900，22.694，22.236，20.633，19.389，
18.214，12.504，11.924，-4.631；MS(EI)：575(M +-15，0.9％)，533(M +-57，6.8％)，485(M +-57-18-15-15，18.9％)；IR：3545，3472，1076.

Claims (10)

1, a kind of steroidal compounds is characterized in that having following molecular formula:
R 1=OH, OAc, OMs, OTs, OTBS or OTBDPS; R 2=X, perhaps R 1, R 2Become 3,5 triatomic rings; Perhaps R 2And R 3Become 5, the two keys of 6-; R 3=OH, OAc, OMs, OTs, OTBS, OTBDPS or X, perhaps R 2And R 3Become 5, the two keys of 6-; R 4=H, OH, SPh or S (CH 2) nSAc, R 5=SPh, perhaps R 4And R 5=S (CH 2) nS, n=2,3; R 4, R 5Become carbonyl, R 5, R 6Become 16,17-two key, perhaps R 5, R 7Become 16,22-ehter bond, R 6=H; Perhaps R 5, R 6Become 16, the two keys of 17-; R 7=R 5, R 7Become 16,22-ehter bond, perhaps R 7, R 8Become carbonyl; R 8=H, perhaps R 7, R 8Become carbonyl;
Wherein, Ac is an ethanoyl, and Ms is a methylsulfonyl, and Ts is a p-toluenesulfonyl, and TBS is that tertiary butyl dimethyl is silica-based, and TBDPS is that tert-butyl diphenyl is silica-based, and X is a halogen, and SPh is a thiophenyl.
2, a kind of steroidal compounds as claimed in claim 1 is characterized in that having following molecular formula: R wherein 1=OH, OAc, OMs, OTs, OTBS or OTBDPS; R 2, R 3=X perhaps becomes 5, the two keys of 6-; R 4=H, OH; Ac, Ms, Ts, TBS and TBDPS are according to claim 1.
3, a kind of steroidal compounds as claimed in claim 1 is characterized in that having following molecular formula: R wherein 3=OH, OAc, OMs, OTs, OTBS or OTBDPS; R 4=H, OH; Ac, Ms, Ts, TBS and TBDPS are according to claim 1.
4, a kind of steroidal compounds as claimed in claim 1 is characterized in that having following molecular formula: R wherein 3=OH, OAc, OMs, OTs, OTBS or OTBDPS; Ac, Ms, Ts, TBS and TBDPS are according to claim 1.
5, a kind of steroidal compounds as claimed in claim 1 is characterized in that having following molecular formula: R wherein 1=OH, OAc, OMs, OTs, OTBS or OTBDPS; R 4, R 5=carbonyl, SPh or S (CH 2) nS, n=2 or 3; Ac, Ms, Ts, TBS and TBDPS are according to claim 1.
6, a kind of steroidal compounds as claimed in claim 1 is characterized in that having following molecular formula: R wherein 1=OH, OAc, OMs, OTs, OTBS or OTBDPS; R 4, R 5=carbonyl, SPh or S (CH 2) nSAc, n=2 or 3; Ac, Ms, Ts, TBS and TBDPS are according to claim 1.
7, a kind of synthetic method of steroidal compounds as claimed in claim 1 is characterized in that by following method synthetic:
In polar solvent, compound 14 and Raney Ni backflow 1-3 days, every mmole compound 14 usefulness 1-2 gram gets compound 15;
In non-protonic solvent and under 10-50 ℃, under organic base catalytic, compound 15 generates sulphonate with the SULPHURYL CHLORIDE reaction, and compound 15, SULPHURYL CHLORIDE and organic bases mol ratio are 1: 1-2: 0.5-2; In polar solvent, sulphonate and inorganic weak bases backflow 1-3 days, the mol ratio of sulphonate and inorganic weak bases is 1: 0.5-3; Products therefrom is dissolved in aceticanhydride, and reaction generated compound 16 in 5-15 hour under organic base catalytic; Wherein the mol ratio of organism, aceticanhydride and organic bases is 1: 2-10: 0.5-2, and wherein SULPHURYL CHLORIDE is methylsulfonyl chloride or Tosyl chloride;
In the buffered soln of the polar solvent and the disodium EDTA aqueous solution, compound 16, potassium hydrogen persulfate and NaHCO 3,, get compound 17 and 18 0-50 ℃ of reaction 2-25 hour; Same method makes compound 17 be converted into compound 18; Compound 16 or 17, potassium hydrogen persulfate and NaHCO 3Mol ratio be 1: 2-8: 8-30; The pH value of buffered soln is 7-9;
In one or more polar solvent and under the Catalyzed by p-Toluenesulfonic Acid, generated compound 19 in compound 18 backflow 10-60 minutes, compound 18 is 1 with the mol ratio of tosic acid: 0.1-0.5;
Aceticanhydride and compound 19 generated compound 20 in 10-60 minute in 100-140 ℃ of reaction under organic base catalytic, and the mol ratio of compound 19, aceticanhydride and organic bases is 1: 2-10: 0.5-2;
In the organic solvent, compound 20, mercaptan, Lewis acid obtains compound 21 0-50 ℃ of reaction 1-4 hour; Compound 20 is 1 with mercaptan and lewis acidic mol ratio: 1-3: 1-2;
In organic solvent, compound 21, catalyzer and aceticanhydride 0-50 ℃ of reaction 5-180 minute, obtain compound 22; The mol ratio of compound 21, aceticanhydride and catalyzer is 1: 2-10: 0.01-2;
In organic solvent, compound 19 or 20, mercaptan and Lewis acid 0-50 ℃ of reaction 1-4 hour, add aceticanhydride, react 5-180 minute, obtain compound 21; Compound 19 or 20, mercaptan, aceticanhydride and lewis acidic mol ratio are 1: 1-3: 10-50: 1-2;
In polar solvent, compound 22 with 25-100 ℃ of reaction 0.5-5 hour, every mmole compound 22 usefulness Raney Ni 1-2 gram must compound 9;
Wherein said Lewis acid is AlCl 3, BF 3Et 2O or TiCl 4Described catalyzer is AlCl 3, BF 3Et 2O, TiCl 4Or HClO 4Described organic bases is triethylamine, pyridine or 4-N, the N-dimethyl aminopyridine; Described non-protonic solvent is CH 2Cl 2, CHCl 3, CCl 4Or ether; Described mercaptan is thiophenol, dithioglycol or dimercaptopropane; Compound 14-22 structural formula is as follows:
8, the synthetic method of steroidal compounds as claimed in claim 7 is characterized in that described Raney Ni is W-2 type or W-6 type.
9, the synthetic method of steroidal compounds as claimed in claim 7 is characterized in that described inorganic weak bases is K 2CO 3, Na 2CO 3, KHCO 3, NaHCO 3, KOAc, NaOAc, wherein Ac is an ethanoyl.
10, a kind of purposes of steroidal compounds as claimed in claim 1 is characterized in that being used for the composite structure formula and is OSW-1 and glucoside unit thereof.
CN 02145066 2002-11-05 2002-11-05 Steride, its systhesis method and use Expired - Fee Related CN1221564C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02145066 CN1221564C (en) 2002-11-05 2002-11-05 Steride, its systhesis method and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02145066 CN1221564C (en) 2002-11-05 2002-11-05 Steride, its systhesis method and use

Publications (2)

Publication Number Publication Date
CN1405176A true CN1405176A (en) 2003-03-26
CN1221564C CN1221564C (en) 2005-10-05

Family

ID=4750756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02145066 Expired - Fee Related CN1221564C (en) 2002-11-05 2002-11-05 Steride, its systhesis method and use

Country Status (1)

Country Link
CN (1) CN1221564C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100408593C (en) * 2006-03-24 2008-08-06 中国科学院上海有机化学研究所 Cholest compound, synthetic method and its use
CN101003561B (en) * 2007-01-19 2011-01-05 中国科学院上海有机化学研究所 Polyhydroxyl steroid compound, synthetic method, and application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867946B1 (en) * 2004-03-25 2007-07-20 Inst Rech Pour Le Dev I R D Et NOVEL INSECTICIDE COMPOSITION AND USE, IN PARTICULAR FOR THE IMPREGNATION OF MOSQUITO NETS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100408593C (en) * 2006-03-24 2008-08-06 中国科学院上海有机化学研究所 Cholest compound, synthetic method and its use
CN101003561B (en) * 2007-01-19 2011-01-05 中国科学院上海有机化学研究所 Polyhydroxyl steroid compound, synthetic method, and application

Also Published As

Publication number Publication date
CN1221564C (en) 2005-10-05

Similar Documents

Publication Publication Date Title
Nicolaou et al. Total synthesis of taxol. 4. The final stages and completion of the synthesis
DK2714710T3 (en) A process for the preparation of intermediates estetrol
CN1176914C (en) Intermediate for preparing 10-deacetylation baccatin III and 10-deacetylation-14 beta hydroxy baccatin III derivatives
Chen et al. The chemistry of taxanes: skeletal rearrangements of baccatin derivatives via radical intermediates
Nemoto et al. A novel strategy for the stereoselective total synthesis of C-17 spiro steroids. Total synthesis of 19-norcanrenone-a formal total synthesis of 19-norspironolactone
CN1405176A (en) Steride, its systhesis method and use
CN106496183A (en) Macrolide derivatives of caffeic acid ester connection and preparation method thereof
CN100408593C (en) Cholest compound, synthetic method and its use
JPH0586021A (en) 10-oxovitamin d analogue
Ho et al. Total synthesis of 9-isocyanoneopupukeanane
US5504222A (en) Transformations of taxol
CN101560236B (en) Method for synthesizing marine polyhydroxyl sterol (25R)-5alpha -cholest-3 beta, 5alpha, 6beta, 26-tetrol
CN1247610C (en) 23 position heteroatom substituted analogue of tiger's eye rohdea saponin OSW-1 kind saponin and its synthesis method and use
US6043382A (en) Transformations of taxol
WO2022057734A1 (en) Key intermediate for synthesizing prostaglandin compounds and preparation method therefor
CN100362014C (en) 17-hydroxy C27 steroid compound and its synthesis and use
Yuan et al. Synthesis and biological activity of a novel C4–C6 bridged paclitaxel analog
CN100343271C (en) C27-steroid antitumour medicine
Herscovici et al. Stereocontrolled routes to functionalized [1, 8-bc] naphthopyran. A study on the total synthesis of quassinoids and tetrahydronaphthalene antibiotics
Klinot et al. Triterpenoid 2, 3-ketols, diols and their acetates: Preparation and conformation of the ring A
JPS6345249A (en) Fluorine derivative of activated vitamin d3
CN101089012B (en) Complete E/F ring-opening synthesis process of 26-chloro-3beta, 16beta-diacetyloxy-22-one-(5-) cholestane (cholestene) with sterioside
CN101003561B (en) Polyhydroxyl steroid compound, synthetic method, and application
CN1887900A (en) Synthesis of 26-bromo-16, 22-dioxy-cholesterol compounds
CN1583784A (en) 17 alpha, 22-dicarboxy furo compound and its use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051005

Termination date: 20111105